Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PPM1B | O75688 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL442252 | 1.00 | TP53 (0.43) | TP53SMN1; SMN2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL22280725 | 1.00 | TP53 (0.43) | TP53SMN1; SMN2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL31503632 | 0.88 | CHRNB2 (0.40) | TP53SMN1; SMN2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL244740 | 0.82 | — | — | |
| SCHEMBL2200767 | 0.82 | TP53 (0.56) | TP53SMN1; SMN2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL2948892 | 0.82 | TP53 (0.56) | TP53SMN1; SMN2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL74396 | 0.82 | TP53 (0.56) | TP53SMN1; SMN2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL1147796 | 0.81 | TP53 (0.44) | TP53SMN1; SMN2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL21380100 | 0.81 | CHRNB2 (0.48) | TP53SMN1; SMN2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL850608 | 0.81 | TP53 (0.44) | TP53SMN1; SMN2CHRNB2CHRNA4CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022081995-A1 | MALT1 MODULATORS AND USES THEREOF | RHEOS MEDICINES, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| CN-113943259-A | Amino acid derivative, preparation method and application thereof | 西安禾渼生物医药有限公司 | 2022-01-18 | — | — | CN | disclosed |
| US-11192877-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2021-12-07 | — | — | US | disclosed |
| US-20210147403-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-05-20 | — | — | US | disclosed |
| US-10882855-B2 | Substituted pyrrolidines as factor XIa inhibitors for the treatment thromboembolic diseases | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-01-05 | — | — | US | disclosed |
| EP-3226688-B1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | MERCK SHARP & DOHME (US) | 2020-07-01 | — | — | EP | disclosed |
| US-10442819-B2 | Tricyclic compounds as inhibitors of mutant IDH enzymes | MERCK SHARP & DOHME CORP. (US) | 2019-10-15 | — | — | US | disclosed |
| US-20190263795-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-08-29 | — | — | US | disclosed |
| US-10336741-B2 | Substituted pyrrolidines as factor XIa inhibitors for the treatment thromboembolic diseases | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-07-02 | — | — | US | disclosed |
| EP-3092229-B1 | PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-03-28 | — | — | EP | disclosed |
| US-20070112005-A1 | mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer | OSI PHARMACEUTICALS, INC. | 2007-05-17 | — | — | US | disclosed |
| JP-2006076931-A | METHOD FOR PRODUCING HIGH PURITY METHYL TRANS-4-CYANOCYCLOHEXANE-1-CARBOXYLATE | ASAHI KASEI FAINKEMU KK | 2006-03-23 | — | — | JP | disclosed |
| JP-2006076931-A | METHOD FOR PRODUCING HIGH PURITY METHYL TRANS-4-CYANOCYCLOHEXANE-1-CARBOXYLATE | ASAHI KASEI FAINKEMU KK | 2006-03-23 | — | — | JP | disclosed |
| US-6723848-B2 | TETRAHYDROBENZOFURAN OR TETRAHYDROBENZOTHIOPHEN OR TETRAHDYROBENZOPYRROLE COMPOUNDS CAN BE AROMATIZED WITH A HYDROGENATION CATALYST IN PRESENCE OF A HYDROGEN ACCEPTOR, DEACYLATION OF AMINO GROUP BY ADDITION OF AN AMINE GROUP | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2004-04-20 | — | — | US | disclosed |
| US-6689885-B2 | REACTING AMINOBENZOTHIOPHENE-3-CARBOXYLIC ESTER COMPOUND WITH NITRILE COMPOUND IN SOLUTION OR SUSPENSION IN A SOLVENT IN THE PRESENCE OF AN ACID TO OBTAIN THIENOPYRIMIDINE COMPOUND | MERCK PATENT GMBH (DE) | 2004-02-10 | — | — | US | disclosed |
| US-20030096994-A1 | Method for producing thienopyrimidines | MERCK PATENT GMBH (DE) | 2003-05-22 | — | — | US | disclosed |
| US-20030078422-A1 | Method for producing benzo annelated heterocycles | MERCK PATENT GMBH (DE) | 2003-04-24 | — | — | US | disclosed |
| US-4389329-A | Meterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 1983-06-21 | — | — | US | disclosed |
| US-4273929-A | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 1981-06-16 | — | — | US | disclosed |
| US-3950405-A | ANTIPLASMIN AGENTS | MITSUBISHI CHEMICAL INDUSTRIES LTD. (JA) | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263795-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | F11, F9, F10 | TP53 3657/4885SMN1; SMN2 4340/4885CHRNB2 4876/4885 |
| US-10882855-B2 | Substituted pyrrolidines as factor XIa inhibitors for the treatment thromboembolic diseases | F11, F9, F10 | TP53 3657/4885SMN1; SMN2 4340/4885CHRNB2 4876/4885 |
| US-20030096994-A1 | Method for producing thienopyrimidines | NUDT1, TYMP, TPMT | TP53 760/4885SMN1; SMN2 485/4885CHRNB2 4143/4885 |
| US-10442819-B2 | Tricyclic compounds as inhibitors of mutant IDH enzymes | IDH3A, IDH2, IDH3B | TP53 6/4885SMN1; SMN2 3984/4885CHRNB2 4769/4885 |
| US-20070112005-A1 | mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer | MTOR, MAPKAP1, RPS6KA1 | TP53 467/4885SMN1; SMN2 4488/4885CHRNB2 4883/4885 |
| US-10336741-B2 | Substituted pyrrolidines as factor XIa inhibitors for the treatment thromboembolic diseases | F11, F9, F10 | TP53 3657/4885SMN1; SMN2 4340/4885CHRNB2 4876/4885 |
| US-20210147403-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | F11, F10, F9 | TP53 3838/4885SMN1; SMN2 4358/4885CHRNB2 4883/4885 |
| US-11192877-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | XDH, HTR1D, RXFP1 | TP53 4076/4885SMN1; SMN2 1091/4885CHRNB2 777/4885 |
| US-20030078422-A1 | Method for producing benzo annelated heterocycles | NAT1, AFF1, SAT1 | TP53 3739/4885SMN1; SMN2 3091/4885CHRNB2 1925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.